Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.

GÖREK DİLEKTAŞLI A., Cetinoglu E., Uzaslan E., BUDAK F., COŞKUN N. F., URSAVAŞ A., ...More

International journal of chronic obstructive pulmonary disease, vol.12, pp.199-208, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2017
  • Doi Number: 10.2147/copd.s118424
  • Journal Name: International journal of chronic obstructive pulmonary disease
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.199-208
  • Keywords: COPD, frequent exacerbator, hospitalized exacerbation, PARC/(CCL-18), OBSTRUCTIVE PULMONARY-DISEASE, SYSTEMIC INFLAMMATION, LUNG-FUNCTION, BIOMARKERS, FREQUENCY, CCL18, MACROPHAGES, VALIDATION, PHENOTYPES, DYSPNEA
  • Bursa Uludag University Affiliated: Yes

Abstract

Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization.